Hydroxyurea-induced leg ulcers treated with a protease-modulating matrix

Archives of Dermatology

Volumn 143, Issue 10, 2007, Pages 1310-1313

  Romanelli, Marco ^a,c   Dini, Valentina ^a   Romanelli, Paolo ^b  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; BUSULFAN; CELLULOSE; HYDROXYUREA; MATRIX METALLOPROTEINASE; PROMOGRAN; SULFADIAZINE SILVER; UNCLASSIFIED DRUG;

AGED; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; COLOR ULTRASOUND FLOWMETRY; COMPRESSION THERAPY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FREEZE DRYING; HUMAN; HYDROGEL DRESSING; LEG ULCER; POLYCYTHEMIA; PRIORITY JOURNAL; SKIN ULCER; THROMBOCYTE; THROMBOCYTHEMIA; WOUND DRESSING; WOUND HEALING;

AGED; AGED, 80 AND OVER; ANIMALS; BANDAGES, HYDROCOLLOID; CATTLE; CELLULOSE, OXIDIZED; COLLAGEN; FEMALE; HUMANS; HYDROXYUREA; LEG ULCER; NUCLEIC ACID SYNTHESIS INHIBITORS; POLYCYTHEMIA VERA; PROTEASE INHIBITORS; THROMBOCYTOSIS; TREATMENT OUTCOME;

EID: 35348952043     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.143.10.1310     Document Type: Article

References (17)

1. Stock CC, Clarke DA, Philips FS, Barclay RK. Sarcoma 180 screening data. Cancer Res. 1960;20(2):193-381.
2. Yarbro JW. Mechanism of action of hydroxyurea. Semin Oncol. 1992;19(3)(suppl 9):1-10.
3. Kennedy BJ, Yarbro JW. Metabolic and therapeutic effects of hydroxyurea in chronic myeloid leukemia. JAMA. 1966;195(12):162-167.
4. Philip PA, Carmichael J, Tonkin K, Ganesan TA, Harris AL. A phase II study of high-dose hydroxyurea and dacarbazine (DTIC) in the treatment of metastatic malignant melanoma. Eur J Cancer. 1994;30A(7):1027-1039.
5. Friedhoff FW, Atamer MA, Thelmo WL. Chronic granulocytic leukemia cutis treated with hydroxyurea. Chemotherapy. 1978;24(5):321-326.
6. Goldberg MA, Brugnara C, Dover GJ, et al. Treatment of sickle cell anemia with hydroxyurea and erythropoietin. N Engl J Med. 1990;323(6):366-372.
7. West WO. Hydroxyurea in the treatment of polycythemia vera: a prospective study of 100 patients over a 20 year period. South Med J. 1987;80(3):323-327.
8. Layton AM, Sheehan-Dare RA, Goodfield MJD. Hydroxyurea in the management of therapy resistant psoriasis. Br J Dermatol. 1989;121(5):647-653.
9. Lori F, Malykh A, Cara A, et al. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science. 1994;266(5186):801- 805.
10. Montefusco E, Alimena G, Gastaldi R, Carlesimo OA, Valesini G, Mandelli F. Unusual dermatologic toxicity of long-term therapy with hydroxyurea in chronic myelogenous leukaemia. Tumori. 1986;72(3):317-321.
11. Daoud MS, Gibson LE, Pittelkow MR. Hydroxyurea dermopathy: a unique lichenoid eruption complicating long-term therapy with hydroxyurea. J Am Acad Dermatol. 1997;36(2, pt 1):178-182.
12. Nguyen TV, Margolis DJ. Hydroxyurea and lower leg ulcers. Cutis. 1993;52(4):217-219.
13. Boyd AS, Neldner KH. Hydroxyurea therapy. J Am Acad Dermatol. 1991;25(3):518-524.
14. Kido M, Tago O, Fujiwara H, Ito M, Niwano H. Leg ulcer associated with hydroxyurea treatment in a patient with chronic myelogenous leukaemia: successful treatment with prostaglandin E1 and pentoxifylline. Br J Dermatol. 1998;139(6):1124-1125.
15. Flores F, Eaglstein WA, Kirsner RS. Hydroxyurea-induced leg ulcers treated with Apligraf. Ann Intern Med. 2000;132(5):417-418.
16. Weinlich G, Schuler G, Greil R, Kofler H, Fritsch P. Leg ulcers associated with longterm hydroxyurea therapy. J Am Acad Dermatol. 1998;39(2, pt 2):372-374.
17. Cullen B, Smith R, McCulloch E, Silcock D, Morrison L. Mechanism of action of PROMOGRAN, a protease modulating matrix, for the treatment of diabetic foot ulcers. Wound Repair Regen. 2002;10(1):16-25.